Dosage: 400mg / 20ml
Specification: 1 vial per box
1. Combination with lenalidomide and Dexamethasone, or Bortezomib and Dexamethasone, is suitable for patients with multiple myeloma who have received at least one treatment.
2. In combination with Pomalidomide and Dexamethasone, patients with multiple myeloma who had received at least two treatments, including lenalidomide and proteosomal enzyme, were treated.
3. Single agent is used for refractory multiple myeloma patients who have received at least three treatments (including protein-body inhibitor, immunomodulator therapy, or a combination of protein-body inhibitor and immunomodulator) for disease progression.
We provide customers with quality products and services.
If you would like to leave us a comment please go to contact us